Geron Corporation (GERN)
| Market Cap | 537.12M |
| Revenue (ttm) | 374,000 |
| Net Income (ttm) | -80.90M |
| Shares Out | 318.80M |
| EPS (ttm) | -0.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $1.73 |
| Previous Close | $1.67 |
| Change ($) | 0.06 |
| Change (%) | 3.59% |
| Day's Open | 1.65 |
| Day's Range | 1.65 - 1.74 |
| Day's Volume | 2,085,806 |
| 52-Week Range | 0.89 - 2.19 |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 120,000 shares of Geron common...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executi...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the opening for patient screening and enrollment of the...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced achievement of fifty percent enrollment in the IMerge P...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that four oral presentations and six poster presentatio...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 80,000 shares of Geron common...
Geron Corporation (GERN) John Scarlett Presents at 2020 Stifel Virtual Healthcare Conference (Transcript)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executi...
Geron Corp (GERN) CEO John Scarlett on Q3 2020 Results - Earnings Call Transcript
Geron (GERN) delivered earnings and revenue surprises of -20.00% and 44.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Geron (NASDAQ:GERN) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share increased 25.00% over the past year to ($0.06), which were in line...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that ten abstracts containing clinical data and analyse...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2020 financial results after the market closes on Thursday, Novemb...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that data from the IMerge Phase 2 trial were published ...
Geron (GERN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it has entered into a loan facility for up to $75 ...
Geron (GERN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 80,000 shares of Geron common...
Geron Corporation (GERN) CEO John Scarlett Presents at H.C. Wainwright Global Investment Conference Transcript
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 270,000 shares of Geron common...
Geron Corp (GERN) CEO John Scarlett on Q2 2020 Results - Earnings Call Transcript
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported financial results for the second quarter ended June 30, ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A.
MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter 2020 financial results after the market closes on Thursday, August...
Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Geron has been struggling lately, but the selling pressure may be coming to an end soon
Is (GERN) Outperforming Other Medical Stocks This Year?
MENLO PARK, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the European Medicines Agency (E...
As of late, it has definitely been a great time to be an investor in Geron.
Investors need to pay close attention to Geron Corporation (GERN) stock based on the movements in the options market lately.
MENLO PARK, Calif., June 12, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that an oral presentation and three p...
Geron Corporation (GERN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Top Ranked Momentum Stocks to Buy for June 9th
Geron Corporation (GERN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Is (GERN) Outperforming Other Medical Stocks This Year?
Top Ranked Momentum Stocks to Buy for June 5th
Top Ranked Momentum Stocks to Buy for June 2nd
Geron Corp (GERN) CEO John Scarlett on Q1 2020 Results - Earnings Call Transcript
Geron (GERN) delivered earnings and revenue surprises of 11.11% and -52.73%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
MENLO PARK, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the first quarter ended March 31, 2020. The Company will host a con...
MENLO PARK, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the closing of its previously announce...
Shares of Geron Corp. GERN, +3.70% plunged 26% in premarket trading Friday, after the biopharmaceutical company's large public offering of stock priced at a 34% discount.
MENLO PARK, Calif., May 22, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of its previously announce...
MENLO PARK, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it intends to offer and sell shar...
MENLO PARK, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced plans for a Phase 3 clinical trial in ...
The bio pharmaceutical announced fresh data on imetelstat that it will present at a key conference next month.
Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
There could be a reason penny stocks trade for under $5, but the returns can be monstrous if there's even minor share price appreciation.
In this David versus Goliath battle, which biotech offers investors a greater return?
About GERN
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It holds rights to imetelstat, a telomerase inhibitor in Phase 2/3 clinical trials, which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. The company was founded in 1990 and is headquartered in Menlo Park, California.
| Industry Biotechnology | IPO Date Jun 30, 1996 |
| CEO John Scarlett | Employees 45 |
| Stock Exchange NASDAQ | Ticker Symbol GERN |
Financial Performance
In 2019, Geron's revenue was $460,000, a decrease of -56.85% compared to the previous year's $1.07 million. Losses were -$68.55 million, 153.7% more than in 2018.
Analyst Forecasts
According to 6 analysts, the average rating for Geron stock is "Strong Buy." The 12-month stock price forecast is 4.00, which is an increase of 131.21% from the latest price.